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OBJECTIVE — Toassesstheefﬁcacyandtolerabilityofalogliptinpluspioglitazoneforinitial
combination therapy in drug-naı ¨ve type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — This 26-week, double-blind, parallel-group
studyrandomized655patientswithinadequatelycontrolledtype2diabetestofourarms:25mg
alogliptin(A25)q.d.monotherapy,30mgpioglitazone(P30)q.d.monotherapy,or12.5(A12.5)
or 25 mg alogliptin q.d. plus pioglitazone (P30) q.d. combination therapy. Primary efﬁcacy was
A1C change from baseline with the high-dose combination (A25  P30) versus each
monotherapy.
RESULTS — Combination therapy with A25  P30 resulted in greater reductions in A1C
(1.70.1%froman8.8%meanbaseline)vs.A25(1.00.1%,P0.001)orP30(1.2
0.1%, P  0.001) and in fasting plasma glucose (2.8  0.2 mmol/l) vs. A25 (1.4  0.2
mmol/l, P  0.001) or P30 (2.1  0.2 mmol/l, P  0.006). The A25  P30 safety proﬁle was
consistent with those of its component monotherapies.
CONCLUSIONS — Alogliptin plus pioglitazone combination treatment appears to be an
efﬁcacious initial therapeutic option for type 2 diabetes.
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B
ecausethepathogenesisoftype2di-
abetes involves defects in both insu-
lin secretion and insulin action,
simpliﬁed,well-tolerated,anddurablyef-
fective combination therapies are being
considered as potential standard initial
treatment strategies to increase the likeli-
hood of achieving sustained glycemic tar-
gets (1–3). Two drug classes that have
complementary modes of action and may
prove efﬁcacious in combination are thia-
zolidinediones (TZDs), which are insulin
sensitizers that increase peripheral glu-
cose uptake, and dipeptidyl peptidase
(DPP)-4 inhibitors, which augment pan-
creatic insulin secretion and also reduce
hepatic glucose output through a sup-
pressive effect on pancreatic glucagon se-
cretion (4,5). This phase 3 study was
conducted in drug-naı ¨ve patients with
type 2 diabetes inadequately controlled
with diet and exercise to evaluate the ef-
fects of initial combination therapy with
the DPP-4 inhibitor alogliptin and the
TZD pioglitazone versus either compo-
nent used alone.
RESEARCH DESIGN AND
METHODS— Eligible subjects were
drug-naı ¨ve (no current antihyperglycemic
medication or 6 days of any such agent
within 3 months of screening) men and
women (aged 18–80 years, with type 2 di-
abetes, A1C 7.5–11%, BMI 23–45 kg/m
2)
who had failed treatment with diet and ex-
ercise for 2 months prior to screening.
Subjects were randomized to 26 weeks of
once-daily treatment with 25 mg alogliptin
(A25) monotherapy, 30 mg pioglitazone
(P30) monotherapy, 12.5 mg alogliptin
plus pioglitazone 30 mg (A12.5  P30)
combination therapy, or 25 mg alogliptin
plus30mgpioglitazone(A25P30)com-
bination therapy (see supplementary Fig. 1
in the online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0159/DC1).
The primary efﬁcacy end point was
A1Cchangefrombaselinetoweek26or
to study end in the intent-to-treat (ITT)
population, with the last observation
carried forward. Secondary glycemic
control variables included A1C and
fasting plasma glucose (FPG) changes
from baseline at each study visit, per-
centage of patients achieving speciﬁc
A1C goals, and frequency of glycemic
rescue according to protocol when
above the speciﬁc FPG or A1C values.
Subgroup analyses by baseline A1C,
sex, age-group, race, ethnicity, and
baseline BMI were also performed.
Changes from baseline were analyzed
using ANCOVA, with treatment and geo-
graphicregionasclasseffectsandbaseline
value as a continuous covariate. The pri-
mary analysis compared A25  P30 with
P30 and with A25, with a two-sided sig-
niﬁcance level of 0.05; if both compari-
sons were statistically signiﬁcant, A12.5 
P30 was then compared with P30.
Adverse events (AEs) were re-
corded, and hypoglycemia was deﬁned
as blood glucose 3.3 mmol/l with
symptoms suggesting low blood glu-
cose or 2.8 mmol/l regardless of
symptoms. Severe hypoglycemia was
deﬁned as any episode requiring assis-
tance from another person.
RESULTS— The study included 655
randomized patients, 654 of which com-
prised both the ITT and safety popula-
tions. Demographic and baseline
characteristicswerewellbalanced(51.1%
female, 80.3% Caucasian, mean age 53
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2, diabetes duration
3 years, baseline mean A1C 8.8%, and
FPG 10.6 mmol/l).
More than 75% of each treatment
group completed the study, with the
highest percentage (82.9%) in the A25 
P30 group (see supplementary Fig. 2 in
the online appendix). Fewer patients in
the combination therapy groups required
hyperglycemic rescue (3.7 and 2.4% with
combination A12.5  P30 and A25 
P30, respectively) than with either P30
(6.1%) or A25 (11.0%) monotherapy.
Each treatment resulted in prompt and
progressive reductions in A1C and FPG
that were sustained throughout the 26
weeks (see supplementary Fig. 3A and B
in the online appendix).
Combination therapy with A25  P30
produced signiﬁcantly larger reductions
from baseline in A1C (1.7%) and FPG
(2.8 mmol/l) than either component
monotherapy (Table 1) (supplementary
Fig.3CandDintheonlineappendix).Fur-
thermore, A12.5  P30 resulted in sig-
niﬁcantly greater A1C and FPG changes
from baseline versus P30. Overall, com-
bination therapy was consistently more
efﬁcacious than either component
monotherapy regardless of age, sex,
race, ethnicity, or baseline BMI.
Both subgroups of patients with A1C
8.5or8.5%hadsigniﬁcantlygreaterre-
ductions in A1C with combination A25 
P30 than those observed with either mono-
therapy. As expected, those with baseline
A1C 8.5% experienced greater reduc-
tions with A25  P30 (2.1%) than with
A25 or P30 alone (1.2 and 1.5%, re-
spectively). Target A1C 7.0% was
achieved by 24% of patients receiving A25,
34%withP30,53%withA12.5P30(P
0.001 vs. P30), and 63% with A25  P30
(P  0.001 vs. either monotherapy). Body
weight remained unchanged with A25
(0.3  0.3 kg) and increased with P30
(2.20.3kg),A12.5P30(2.50.3
kg), and A25  P30 (3.1  0.3 kg; P 
0.05 vs. P30 and A25).
IncidenceofAEswaslowestwithA25
(54.9%) and highest with A25  P30
(65.2%). Most frequent AEs were head-
ache (all treatment groups), back pain
and urinary tract infection (A25  P30),
and peripheral edema (P30). Incidence of
study drug–related AEs, as judged by the
investigators, was lowest with A25
(13.4%) and highest with A25  P30
(21.3%). Discontinuations because of
AEs were least frequent with A25 (1.8%)
and most frequent with P30 (4.3%). One
serious AE (SAE) occurred with A25 and
one with A12.5P30, whereas six SAEs
(3.7%) occurred with P30 and eight SAEs
(4.9%) with A25  P30. No congestive
heart failure or bone fracture events were
reported.Hypoglycemiawasuncommon,
with the highest incidence of mild hypo-
glycemia in the A25  P30 group (ﬁve
patients [3.0%]), and there were no re-
ports of severe hypoglycemia.
CONCLUSIONS — Initial combina-
tion therapy with the DPP-4 inhibitor
alogliptin (25 mg) plus the TZD piogli-
tazone (30 mg) once daily for 26 weeks
signiﬁcantly improved glycemic control
relative to monotherapy with either
component in patients with type 2 dia-
betes inadequately controlled with life-
style interventions. Despite a relatively
high baseline A1C, this treatment strat-
egy allowed nearly two-thirds of the pa-
tientstoachieveA1C7.0%.Thesafety
proﬁles of alogliptin and pioglitazone
administered together or separately
were generally consistent with those
previously reported for these two drug
classes individually (6,7).
In summary, initial combination
treatment with alogliptin and pioglita-
zone appears to be safe and was highly
effective in short-term exposure and
may be considered as an initial thera-
peutic option for type 2 diabetic pa-
tients not achieving adequate glycemic
control with lifestyle changes alone or
in those who cannot tolerate metformin
therapy.
Table 1—Results of glycemic control end points
25 mg
alogliptin q.d.
30 mg pioglitazone
HCl q.d.
12.5 mg alogliptin 
30 mg pioglitazone
25 mg alogliptin 
30 mg pioglitazone
n 164 163 163 164
Baseline values
A1C (%) 8.80  0.988 8.76  1.005 8.85  1.039 8.80  0.962
FPG (mmol/l) 10.5  2.84 10.5  3.01 11.0  3.34 10.2  2.76
Changes from baseline at week 26
A1C (%) 0.96  0.081 1.15  0.083 1.56  0.081* 1.71  0.081*†
A1C by baseline A1C subgroups
8.5% 0.67 (n  70) 0.76 (n  68) 1.25 (n  67)* 1.20 (n  63)*†
8.5% 1.15 (n  90) 1.47 (n  85) 1.79 (n  91) 2.07 (n  95)*†
9.0% 0.77 (n  97) 1.00 (n  92) 1.33 (n  92)* 1.30 (n  93)*†
9.0% 1.20 (n  63) 1.38 (n  61) 1.91 (n  66)* 2.30 (n  65)*†
Clinical response, A1C
6.5% 19 (11.6) 27 (16.6) 43 (26.4)* 45 (27.4)†
7.0% 40 (24.4) 55 (33.7) 87 (53.4)* 103 (62.8)*†
Reduction 1.0% 71 (43.3) 89 (54.6) 111 (68.1) 124 (75.6)*†
Reduction 2.0% 29 (17.7) 32 (19.6) 54 (33.1)* 56 (34.1)*†
FPG (mmol/l) 1.4  0.18 2.1  0.18 2.7  0.18* 2.8  0.18*†
Marked hyperglycemia 72/162 (44.4) 60/157 (38.2) 50/162 (30.9) 41/162 (25.3)*†
Hyperglycemic rescue 18/160 (11.3) 10/156 (6.4) 6/160 (3.8) 4/161 (2.5)†
Body weight (kg) 0.29  0.291 2.19  0.302 2.51  0.296 3.14  0.295*†
Data are least square mean changes  SE (with P values from an ANCOVA model) or n (%) (with P values from extended Mantel-Haenszel tests comparing overall
incidence between treatment groups). *P  0.05 vs. 30 mg pioglitazone HCl alone; †P  0.05 vs. 25 mg alogliptin alone.
Rosenstock and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 2407Acknowledgments— J.R. is a consultant and
has conducted research trials for Takeda,
Amylin Pharmaceuticals, Boehringer In-
gelheim, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Johnson & Johnson, Mann-
Kind, Merck, and Novartis Pharmaceuticals.
S.E.I. has been an advisor for Takeda, Amylin
Pharmaceuticals, and Merck. J.S. has been a
speaker and advisor to Takeda, GlaxoSmith-
Kline, Merck Sharp & Dohme, and Novartis
Pharmaceuticals. P.R.F. is an employee of
Takeda Global Research & Development Cen-
ter. C.A.W. is an employee of Takeda Global
Research & Development Center. Q.M. is an
employeeofTakedaGlobalResearch&Devel-
opment Center and owns stock in Takeda
Pharmaceuticals. No other potential conﬂicts
of interest relevant to this article were
reported.
Assistance with manuscript development
wasprovidedbyBethDunningLower,PhD,of
PharmaWrite, and by Daniela Ilijevski, and
supported by Takeda Pharmaceuticals North
America Inc.
References
1. Hamann A, Garcia-Puig J, Paul G,
Donaldson J, Stewart M. Comparison of
ﬁxed-dose rosiglitazone/metformin com-
bination therapy with sulphonylurea plus
metformininoverweightindividualswith
type 2 diabetes inadequately controlled
on metformin alone. Exp Clin Endocrinol
Diabetes 2008;116:6–13
2. Blonde L, Joyal S, Henry D, Howlett H.
Durable efﬁcacy of metformin/gliben-
clamide combination tablets (Gluco-
vance) during 52 weeks of open-label
treatment in type 2 diabetic patients with
hyperglycaemia despite previous sulpho-
nylurea monotherapy. Int J Clin Pract
2004;58:820–826
3. Reynolds JK, Neumiller JJ, Campbell RK.
Janumet: a combination product suitable
for use in patients with type 2 diabetes.
Expert Opin Invest Drugs 2008;17:
1559–1565
4. Rosenstock J, Zinman B. Dipeptidyl
peptidase-4 inhibitors and the manage-
ment of type 2 diabetes mellitus. Curr
Opin Endocrinol Diabetes Obes 2007;
14:98–107
5. Rosenstock J, Kim SW, Baron MA,
Camisasca RP, Cressier F, Couturier A, De-
jager S. Efﬁcacy and tolerability of initial
combination therapy with vildagliptin and
pioglitazone compared with component
monotherapy in patients with type 2 diabe-
tes. Diabetes Obes Metab 2007;9:175–185
6. Inzucchi SE, McGuire DK. New drugs for
the treatment of diabetes: part II: Incretin-
based therapy and beyond. Circulation
2008;117:574–584
7. McGuire DK, Inzucchi SE. New drugs for
the treatment of diabetes mellitus: part I:
thiazolidinediones and their evolving
cardiovascular implications. Circulation
2008;117:440–449
Alogliptin and pioglitazone initial therapy
2408 DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 care.diabetesjournals.org